As the curtain falls on 2024, there’s been a surge in job reductions within the medtech sector. **Sean Whooley, Associate Editor, and Chris Newmarker, Editor-in-Chief** The medical device sector is concluding the year with an increase in job cuts. Reports […]
Medtech Workforce Reductions: Recent Company Layoffs Overview Read More »
Lungpacer Medical announced it has obtained premarket approval from the FDA for their leading AeroPace neurostimulation device. The AeroPace system utilizes neurostimulation through an electrode-equipped cardiovascular catheter and a software-driven management system. It periodically stimulates the phrenic nerve via the
Lungpacer Medical Secures FDA Approval for AeroPace Neurostimulation System Read More »
Profound Medical Corp. (Nasdaq:PROF) announced today the pricing of its underwritten public offering, slated to generate roughly $35 million. Based in Toronto, the company will be distributing approximately 4.7 million common stock shares at $7.50 each. Additionally, underwriters have been
Profound Medical Launches $35 Million Public Offering Read More »
DermaSensor, a company known for its skin cancer detection devices, has confirmed through an SEC Form D filing, the successful sale of nearly $9 million in equity. The filing, dated December 4, indicates that the initial sale took place on
DermaSensor Secures $8.9 Million to Enhance Skin Cancer Detection Technology Read More »
**Intuitive Surgical** (Nasdaq:ISRG) unveiled results from a comprehensive analysis of surgical results spanning various robotic operations. The prestigious Annals of Surgery has published a thorough examination of surgical outcomes over a 30-day period across seven cancer-related surgeries. This analysis compared
Insights Reveal Advantages of da Vinci Robotic Surgery Across Seven Cancer Procedures Read More »
EpicentRx, a privately-operated biopharmaceutical entity, has disclosed that their investigational therapy, AdAPT-001, has been awarded a Fast Track designation by the US Food and Drug Administration. AdAPT-001, combined with immune checkpoint inhibitors like nivolumab or atezolizumab, targets the treatment of
Pfizer Inc. will feature the latest innovations from its expanding hematology and breast cancer lines at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Through over
Pfizer Highlights Leadership in Breast Cancer and Hematology at ASH and SABCS Events Read More »
Cambrex, a prominent global contract development and manufacturing organization (CDMO), has announced a new partnership with Eli Lilly and Company (Lilly) to facilitate speedy access to clinical development resources for Lilly’s biotech partners. In this collaboration, Cambrex will join forces
Cambrex Collaborates with Lilly to Enhance Biotech Partner Manufacturing Efforts Read More »
Global pharmaceutical company Merck, also referred to as MSD outside the US and Canada, has launched the phase 3 MOVe-NOW clinical trial. The trial aims to assess the effectiveness of Lagevrio (molnupiravir), an investigative oral antiviral medication, in treating Covid-19
A study spearheaded by the National Institutes of Health (NIH) has demonstrated that progress in cancer prevention and screening has significantly reduced mortality rates in five common cancer types over the last 45 years, surpassing the impact of advancements in